Victory Capital Management Inc. Purchases 386,668 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Victory Capital Management Inc. lifted its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 12.8% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,410,142 shares of the company's stock after purchasing an additional 386,668 shares during the quarter. Victory Capital Management Inc. owned 0.30% of Teva Pharmaceutical Industries worth $52,414,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Burford Brothers Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 2.1% during the first quarter. Burford Brothers Inc. now owns 155,876 shares of the company's stock valued at $2,396,000 after purchasing an additional 3,189 shares during the last quarter. Hara Capital LLC grew its holdings in Teva Pharmaceutical Industries by 4.7% in the 1st quarter. Hara Capital LLC now owns 31,814 shares of the company's stock valued at $489,000 after buying an additional 1,434 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 197,885.2% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after purchasing an additional 22,044,407 shares in the last quarter. IFM Investors Pty Ltd grew its holdings in shares of Teva Pharmaceutical Industries by 11.6% during the 1st quarter. IFM Investors Pty Ltd now owns 231,028 shares of the company's stock worth $3,551,000 after purchasing an additional 23,941 shares in the last quarter. Finally, D.A. Davidson & CO. grew its holdings in shares of Teva Pharmaceutical Industries by 6.4% during the 1st quarter. D.A. Davidson & CO. now owns 94,586 shares of the company's stock worth $1,454,000 after purchasing an additional 5,667 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. Wall Street Zen downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective for the company. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $21.00 to $23.00 in a research report on Monday, May 12th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Buy" and an average price target of $24.71.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president owned 9,989 shares in the company, valued at $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Down 0.1%

Shares of TEVA stock traded down $0.01 on Tuesday, hitting $16.30. 10,215,216 shares of the stock were exchanged, compared to its average volume of 10,344,046. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. The firm has a market capitalization of $18.69 billion, a P/E ratio of -14.17, a price-to-earnings-growth ratio of 0.96 and a beta of 0.60. The business has a 50-day moving average of $16.98 and a 200 day moving average of $16.87. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. Teva Pharmaceutical Industries's revenue was up 1.9% on a year-over-year basis. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.